Experts on non–small cell lung cancer review clinical trial data and discuss their evolving treatment practices for patients with EGFR alterations.
EP. 1: Biomarker Testing in Non–Small Cell Lung Cancer
A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.
EP. 2: NSCLC: Molecular Testing in the Metastatic Setting
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
EP. 3: NGS Testing Challenges and Considerations in NSCLC
Expert perspectives on next-generation sequencing for patients with non–small cell lung cancer, highlighting challenges and the differences between RNA and DNA testing.
EP. 4: Frontline Treatment for EGFR-Mutated Lung Cancer
An overview of frontline treatment options for patients with EGFR-mutated non–small cell lung cancer.
EP. 5: FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.
EP. 6: MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC
Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.